Skip to main content
. Author manuscript; available in PMC: 2009 Sep 15.
Published in final edited form as: J Immunol. 2008 Sep 15;181(6):4272–4278. doi: 10.4049/jimmunol.181.6.4272

FIGURE 1.

FIGURE 1

Survival of syngeneic or allogeneic islet grafts in mice with diabetes. A, NOD mice with hyperglycemia received a transplant of syngeneic islet grafts and were treated with TTP488 (n = 8) or control peptide (n = 11) as indicated in the Materials and Methods. The percentage of nondiabetic mice is shown. There was a significant prolongation of the survival of islets in mice treated with TTP488 (p < 0.001). B, C57BL/6 mice with STZ-induced diabetes were transplanted with BALB/c islets and treated with TTP488 (n = 8) or control protein (n = 8). There was a significant prolongation of graft survival with the RAGE antagonist (p < 0.001).